Lee Weisbecker, Staff Writer - Triangle Business Journal
Durham-based Trimeris and its merger partner, Synageva BioPharma Corp. of Lexington, Mass., have set Nov. 2 as the date for their respective shareholders to vote on the deal.
Synageva, a privately held firm, develops various protein agents. Trimeris’ key product is the anti-HIV drug Fuzeon.
Synageva is buying Trimeris and, upon closing, the combined company will be named Synageva BioPharma Corp.
Trimeris (Nasdaq: TRMS) shareholders of record as of last Sept. 21 will be allowed to vote on the merger, which is an all-stock transaction valued at about $35 million. Trimeris shares currently trade in the $2.74 range, near the 52-week high of $2.96, according to Yahoo Finance.